New CRISPR Tools to Correct Pathogenic Mutations in Usher Syndrome

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Inherited retinal degenerations are a major cause of blindness in the UK.
• Current gene therapy, like Luxturna for RPE65 mutations, faces limitations with large genes (e.g., USH2A) and toxic mutations due to adeno-associated virus (AAV) packaging limits.
• Usher Syndrome type II, caused by USH2A gene mutations, is a common form of inherited deaf-blindness.

Purpose of the Study:

• To review the potential of CRISPR technology for treating inherited retinal degenerations, specifically targeting the large USH2A gene.
• To explore CRISPR as an alternative to gene replacement therapy for conditions exceeding AAV packaging capacity.
• To address the challenge of delivering gene editing tools for USH2A mutations within a single AAV vector.

Main Methods:

• Review of CRISPR technology derived from bacterial defense mechanisms.
• Discussion of CRISPR's application in precisely editing small genetic variations (insertions, deletions, base transitions).
• Focus on the feasibility of delivering CRISPR tools for USH2A gene correction via AAV vectors.

Main Results:

• CRISPR technology presents a viable strategy for precise gene editing of mutations within the large USH2A gene.
• CRISPR-based tools can be engineered to fit within AAV vectors, overcoming current delivery limitations.
• This approach allows for correction of mutations without needing to deliver the entire large gene sequence.

Conclusions:

• CRISPR gene editing holds significant promise for developing novel therapies for Usher Syndrome type II and other inherited retinal degenerations.
• Ultra-compact gene editing therapies utilizing CRISPR could overcome the size limitations of traditional gene replacement, offering new hope for treating blindness in young people.
• Precise correction of USH2A mutations via CRISPR editing is a key advancement in combating this common subtype of Usher Syndrome.